↓ Skip to main content

Dove Medical Press

Article Metrics

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Overview of attention for article published in Biologics: Targets & Therapy, February 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#21 of 188)
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
1 tweeter
patent
4 patents
video
1 video uploader

Citations

dimensions_citation
161 Dimensions

Readers on

mendeley
184 Mendeley
Title
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Published in
Biologics: Targets & Therapy, February 2013
DOI 10.2147/btt.s29965
Pubmed ID
Authors

Paul Licciardi, Ververis, Hiong, Karagiannis

Abstract

Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addition to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene expression, disturb homeostasis, and contribute to neoplastic growth. The family of HDAC inhibitors is large and diverse. It includes a range of naturally occurring and synthetic compounds that differ in terms of structure, function, and specificity. HDAC inhibitors have multiple cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation, and apoptosis in malignant cells. HDAC inhibitors have the potential to be used as monotherapies or in combination with other anticancer therapies. Currently, there are two HDAC inhibitors that have received approval from the US FDA for the treatment of cutaneous T-cell lymphoma: vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax). More recently, depsipeptide has also gained FDA approval for the treatment of peripheral T-cell lymphoma. Many more clinical trials assessing the effects of various HDAC inhibitors on hematological and solid malignancies are currently being conducted. Despite the proven anticancer effects of particular HDAC inhibitors against certain cancers, many aspects of HDAC enzymes and HDAC inhibitors are still not fully understood. Increasing our understanding of the effects of HDAC inhibitors, their targets and mechanisms of action will be critical for the advancement of these drugs, especially to facilitate the rational design of HDAC inhibitors that are effective as antineoplastic agents. This review will discuss the use of HDAC inhibitors as multitargeted therapies for malignancy. Further, we outline the pharmacology and mechanisms of action of HDAC inhibitors while discussing the safety and efficacy of these compounds in clinical studies to date.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 184 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 2%
Netherlands 2 1%
United States 2 1%
Egypt 1 <1%
Chile 1 <1%
Slovakia 1 <1%
India 1 <1%
Unknown 173 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 46 25%
Researcher 38 21%
Student > Master 30 16%
Student > Bachelor 18 10%
Student > Doctoral Student 15 8%
Other 37 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 64 35%
Medicine and Dentistry 34 18%
Biochemistry, Genetics and Molecular Biology 25 14%
Chemistry 25 14%
Unspecified 13 7%
Other 23 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2018.
All research outputs
#1,916,612
of 11,929,279 outputs
Outputs from Biologics: Targets & Therapy
#21
of 188 outputs
Outputs of similar age
#22,561
of 134,879 outputs
Outputs of similar age from Biologics: Targets & Therapy
#3
of 7 outputs
Altmetric has tracked 11,929,279 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 188 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 134,879 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.